Search

Displaying results 5211 - 5220 of 7180 in total
  1. Drug

    Plozalizumab

    go.drugbank.com/drugs/DB12520
    Investigational

    The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. … Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation.

  2. Drug

    13-deoxydoxorubicin

    go.drugbank.com/drugs/DB05706
    Investigational

    GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.

  3. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause.

  4. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    [A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. … [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]

  5. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. … NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.

  6. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions

  7. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488]. … The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758].

  8. Drug

    Edivoxetine

    go.drugbank.com/drugs/DB09184
    Investigational

    Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012. … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant

  9. Drug

    KB109

    go.drugbank.com/drugs/DB16531
    Experimental

    KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.

  10. Drug

    Ritiometan

    go.drugbank.com/drugs/DB13267
    Approved

    Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.